CD14 and neoplasm: CD14+ monocytes showed significantly decreased CD16 surface expression when cultured with cetuximab-coated tumor cells (Fig. 5e, p = 0.004), concomitant with upregulation of M1 and down-regulation of M2 markers (Fig. 5a-d).